InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (10 ops.)
Explore the complete record of transactions filed by TRUFFLE CAPITAL SAS, CEO & Co-Founder of Truffle Capital / co-founder of ABIVAX. Officer active across 3 companies, notably ABIVAX. In total, 22 filings have been published. Total volume traded: €27m. The latest transaction was filed on 2 February 2026 — Acquisition. Regulator: AMF. The full history is accessible without signup.
Declarations22 total
€5m2,136,751 shares@ €2.349.46% mcap25.9% of flow
ActionAcquisition hors marché
2026DD1092720·
Ideal exit: 30 Oct 2026 (T+270)
€21,99916,176 shares@ €1.360.042% mcap0.1% of flow
ActionAcquisition hors marché
2025DD1064624·
Ideal exit: 17 Jul 2026 (T+270)
€25,00018,382 shares@ €1.360.047% mcap0.1% of flow
ActionAcquisition hors marché
2025DD1059546·
Ideal exit: 17 Apr 2026 (T+270)
€1m117,630 shares@ €9.09690.011% mcap6.3% of flow
ActionEuronext Paris
2024DD999290·
€350,00035,000 shares@ €10.000.0037% mcap2.0% of flow
ActionEuronext Paris
2024DD996831·
€423,84341,270 shares@ €10.270.0045% mcap2.5% of flow
ActionEuronext Paris
2024DD995512·
€3m2,479,411 shares@ €1.3817.8% of flow
Titre de créanceEuroclear
2024DD986552·
€2m1,419,871 shares@ €1.5611.5% of flow
ActionEuronext Paris
2024DD949188·
€725,00375,000 shares@ €9.66670.0077% mcap4.2% of flow
ActionEuronext Paris
2023DD943554·
€19,3832,062 shares@ €9.400.0002% mcap0.1% of flow
ActionEuronext Paris
2023DD942355·
US$3m265,000 shares@ US$11.600.033% mcap18.0% of flow
ActionNasdaq Global Market
2023DD934753·
Ideal exit: 16 Jul 2024 (T+270)
€3m16.088 shares@ €192,781.000.033% mcap18.2% of flow
ActionEuronext Paris
2023DD920130·
€3m192,781 shares@ €16.08810.033% mcap18.2% of flow
ActionEuronext Paris
2023DD926614·
€4m129,427 shares@ €30.905599.4% of flow
ActionEuronext Growth Paris
2023DD920136·
€25,030627 shares@ €39.91950.022% mcap0.6% of flow
ActionEuronext Growth Paris
2023DD915287·
Ideal exit: 11 Mar 2024 (T+270)
€4m224,729 shares@ €17.220.041% mcap22.7% of flow
ActionEuronext Paris
2023DD914258·
€8m6,363,034 shares@ €1.3243.6% of flow
ActionEuronext Paris
2023DD888174·
€190,8916,363,034 shares@ €0.031.0% of flow
BSAREuronext Paris
2023DD888175·
€1m215,000 shares@ €6.23020.014% mcap7.8% of flow
ActionEuronext Paris
2022DD875280·
€4m1,637,931 shares@ €2.32100.0% of flow
ActionEuronext Paris
2022DD862308·
€2m197,000 shares@ €8.360.017% mcap33.7% of flow
ActionEuronext Paris
2022DD860537·
Ideal exit: 30 May 2023 (T+270)
€3m120,000 shares@ €27.000.034% mcap66.3% of flow
ActionEuronext Paris
2021DD797396·
22 of 22 declarations
About TRUFFLE CAPITAL SAS
TRUFFLE CAPITAL SAS is the holding entity behind Truffle Capital, a leading European venture capital firm active in biotech, medtech and fintech. The individual most closely associated with this entity is Dr. Philippe Pouletty, co-founder and CEO of Truffle Capital. According to Truffle Capital and Abivax, he is a serial biotech and medtech entrepreneur, inventor and investor with more than 30 years of experience building and scaling life-science companies in Europe and the United States. Philippe Pouletty founded or co-founded several high-profile companies, including ABIVAX, created in 2013 to develop innovative therapies in immunology and inflammatory diseases. He served as Chairman of Abivax’s Board from the company’s inception until August 2022 and has continued as a board member since then, reflecting his long-term strategic involvement in the company’s governance. Truffle Capital also highlights his role in the creation of Affluent Medical, a publicly listed medtech company on Euronext Paris focused on minimally invasive implants for cardiac and urological conditions. His career is characterized by a “business builder” approach: identifying breakthrough technologies, assembling leadership teams, securing financing, and guiding companies through clinical development and industrial scaling toward IPOs or strategic exits. Truffle Capital presents several emblematic successes linked to his leadership, notably the creation of Abivax, the development of Affluent Medical, and other medtech and biotech ventures. This has helped establish Truffle as a reference investor in French life sciences innovation. In terms of expertise, Philippe Pouletty is positioned at the intersection of scientific value creation, venture financing, governance of innovative companies, and the transition from research programs to listed or industrial assets. His profile is further strengthened by institutional recognition, including the Légion d’honneur and an American Liver Foundation award, underscoring his credibility in the life sciences ecosystem.
